NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $4.10 -0.07 (-1.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.04 -0.06 (-1.46%) As of 08/1/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Corvus Pharmaceuticals Stock (NASDAQ:CRVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corvus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.96▼$4.1250-Day Range$3.49▼$4.7552-Week Range$2.54▼$10.00Volume604,705 shsAverage Volume436,656 shsMarket Capitalization$279.50 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. Read More Corvus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCRVS MarketRank™: Corvus Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 690th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Corvus Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,893,541.00 in company stock.Percentage Held by Insiders28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesCompanies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comCantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)June 14, 2025 | theglobeandmail.comDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.August 2 at 2:00 AM | American Alternative (Ad)Corvus Nicks up on Releasing Preclinical Trial DataJune 11, 2025 | baystreet.ca3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJune 4, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comCorvus Pharmaceuticals Shares Surge on Study Data Evaluating SoquelitinibMay 10, 2025 | marketwatch.comSee More Headlines CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $5.35 at the start of the year. Since then, CRVS shares have decreased by 23.4% and is now trading at $4.10. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Read the conference call transcript. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' top institutional investors include Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.25%) and Masso Torrence Wealth Management Inc. (0.07%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Corvus Pharmaceuticals$15.00 High Price Target$21.00 Low Price Target$11.00 Potential Upside/Downside+265.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-24.04% Return on Assets-13.90% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book8.04Miscellaneous Outstanding Shares68,170,000Free Float48,741,000Market Cap$279.50 million OptionableOptionable Beta0.42 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CRVS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.